Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

Hepatitis and HIV news

Show

From To
Achillion Achieves 100 Percent Sustained Virologic Response Rate (SVR4) From an Eight Week Phase 2 Trial Evaluating a Ribavirin-Free Regimen of ACH-3102 and Sofosbuvir for Genotype 1 HCV ("Proxy Study")

Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) today announced interim results from an ongoing Phase 2 proxy study evaluating ACH-3102, Achillion's second-generation NS5A inhibitor, in combination with sofosbuvir, without ribavirin, for eight weeks of treatment in patients with treatment-naïve genotype 1 chronic hepatitis C virus (HCV) infection.

Published
18 August 2014
From
Achillion press release
NICE consults on further draft guidance on the drug sofosbuvir (Sovaldi) for treating hepatitis C

In further draft guidance NICE has recommended sofosbuvir (Sovaldi, Gilead Sciences) as a treatment option for some people with chronic hepatitis C. The positive recommendation follows receipt of additional information about the drug’s cost effectiveness from the manufacturer.

Published
15 August 2014
From
NICE
UK cost body backs pricey Gilead hepatitis pill for some patients

Carole Longson, director of the NICE Centre for Health Technology Evaluation, said on Friday it was now provisionally recommending Sovaldi, also known as sofosbuvir, as a cost-effective treatment for some people with chronic hepatitis C.

Published
15 August 2014
From
Reuters
OTP patients, ideal for new hepatitis C medication, put on bottom of list by payers

Sovaldi, approved by the Food and Drug Administration (FDA) last year for the treatment of chronic hepatitis C (HCV), has a success rate better than 90 percent, and is ideal for use in opioid treatment programs (OTPs), yet payers are balking at covering it for patients who have a history of a substance use disorder (SUD), ADAW has learned.

Published
14 August 2014
From
Alcohol & Drug Abuse Weekly
Study in Malawi shows importance of screening HIV-positive patients for HBV co-infection and using tenofovir-containing regimens

Hepatitis B virus (HBV) genotype A1 infection is associated with poor virological control and the rapid emergence of drug resistance among people living with HIV who are

Published
14 August 2014
By
Michael Carter
Vertex to stop selling hepatitis C drug Incivek, once a blockbuster, in October

Vertex Pharmaceuticals has notified health care providers that it will stop selling its first blockbuster drug, Incivek, in about two months.

Published
13 August 2014
From
Boston Business Journal (blog)
Gilead in talks with Indian drugmakers to sell Sovaldi at cut-rate prices

Share Tools Comment Print Contact Author Reprint Indian drugmakers have a shot at bringing Gilead Sciences' ($GILD) hot new hepatitis C drug to their country. The California-based company is in talks with "a handful" of Indian pharmas to take Sovaldi (sofosbuvir) to that country and other developing nations at a fraction of the U.S. price.

Published
11 August 2014
From
Fierce Pharma
Why the Hepatitis Cure Sovaldi Is a Budgetary Disaster for Prisons

There is only one group in the United States with a constitutional right to medical care: prisoners. That is why the introduction of an expensive new drug to treat hepatitis C is forcing prison administrators to begin wrestling with a big dilemma — save their budgets or treat their inmates.

Published
07 August 2014
From
New York Times
What Will the new Hepatitis C Medicines do to Medicare Part D?

In the latest salvo fired over the cost of hepatitis C treatments, a new report projects that the cost of these drugs – including the Sovaldi medication sold by Gilead Sciences – will increase 2015 federal spending by Medicare Part D between $2.9 billion to $5.8 billion.

Published
05 August 2014
From
Wall Street Journal
Study predicts hepatitis C will become a rare disease in 22 years

Effective new drugs and screening would make hepatitis C a rare disease by 2036, according to a computer simulation conducted by The University of Texas MD Anderson Cancer Center and the University of Pittsburgh Graduate School of Public Health.

Published
05 August 2014
From
Eurekalert Medicine & Health

Filter by country